IDH1 and central nervous system cancer: Notably, this group exhibited survival outcomes that appeared distinct from other IDH1/2-mutant astrocytoma clusters, not reaching median overall survival after 20 years of assessment, despite 44% of gliomas in this cluster being histopathologically classified as grade 3 or 4.